ROBOTIC PANCREATODUODENECTOMY: PATIENT SELECTION, VOLUME CRITERIA, AND TRAINING PROGRAMS

L. R. Jones¹,², M. J. W. Zwart², I. Q. Molenaar³, B. Groot Koerkamp⁴, M. E. Hogg⁵, M. A. Hilal*¹, M. G. Besselink*², for the Dutch Pancreatic Cancer Group

¹Department of General Surgery, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy
²Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
³Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
⁴Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
⁵Department of Surgery, NorthShore University HealthSystem, Chicago, IL, USA

ABSTRACT

Introduction: There has been a rapid development in minimally invasive pancreas surgery in recent years. The most recent innovation is robotic pancreaticoduodenectomy. Several studies have suggested benefits as compared to the open or laparoscopic approach. This review provides an overview of studies concerning patient selection, volume criteria, and training programs for robotic pancreaticoduodenectomy and identified knowledge gaps regarding barriers for safe implementation of robotic pancreaticoduodenectomy.

Materials and methods: A PubMed search was conducted concerning patient selection, volume criteria, and training programs in robotic pancreaticoduodenectomy.

Results: A total of 20 studies were included. No contraindications were found in patient selection for robotic pancreaticoduodenectomy. The consensus and the Miami guidelines advice is a minimum annual volume of 20 robotic pancreaticoduodenectomy procedures per center, per year. One training program was identified which describes superior outcomes after the training program and shortening of the learning curve in robotic pancreaticoduodenectomy.

Conclusion: Robotic pancreaticoduodenectomy is safe and feasible for all indications when performed by specifically trained surgeons working in centers who can maintain a minimum volume of 20 robotic pancreaticoduodenectomy procedures per year. Large
proficiency-based training program for robotic pancreateoduodenectomy seem essential to facilitate a safe implementation and future research on robotic pancreateoduodenectomy.

Key words: Whipple; pancreateoduodenectomy; robot; robotic; robot-assisted; patient selection; volume criteria; training

INTRODUCTION

Robotic pancreateoduodenectomy (RPD) aims to minimize the impact of this extensive surgical procedure and hence enhance patient recovery. Several studies have suggested superior outcomes as compared to open and laparoscopic pancreateoduodenectomy. A Pan-European propensity score matched study showed superior outcomes to open pancreateoduodenectomy (OPD) in terms of time to recovery and to laparoscopic pancreateoduodenectomy in terms of conversion levels (1). A single-center propensity-matched analysis reported a lower rate of clinically relevant pancreatic fistulas after RPD as compared to OPD (2).

However, several questions arise regarding the potential for safe implementation of a highly complex procedure as RPD. First, which patients should be selected for RPD. Are there contraindications or is RPD safe/superior for all indications? (3–8). Second, is there a minimum annual volume for safe implementation of RPD. There have been several studies describing volume criteria for RPD (3, 9–15). This review sets this out to describe the outcomes related to volume. Third, how long is the learning curve for RPD and how to minimize patient risk during this period? Multiple studies describe a considerable learning curve for RPD (9, 12–15). This highlights the importance of specific training programs for RPD to shortening the learning curve and minimize or even exclude any patient risk during this phase. This review describes the training programs for RPD and other robot pancreas surgery found in the literature (4, 16–18).

This review sets out to give insight about patient selection, volume criteria, and training programs for RPD and what needs to be studied for safe implementation of RPD.

MATERIALS AND METHODS

We conducted a systematic literature search using PubMed, using MESH terms and free text related to patient selection, volume criteria, or training programs for RPD. In addition, studies describing training programs for other robotic pancreas surgery were included. We included randomized controlled trials, retrospective and prospective cohort studies, and systematic reviews. Only full text articles were included. Inaccessible articles, non-English articles, and publications before 1998 were excluded. Studies describing RPD but not in relation to patient selection and volume criteria were excluded. Finally, studies not describing robotic surgery were excluded except for training programs. The initial screening was performed on title and abstract in PubMed. Articles that were selected after title and abstract screening were screened on full text. The literature search is described in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart under “RESULTS” (Fig. 1).

RESULTS

Overall, we identified 58 studies. After title and abstract screening, we were left with 22 studies to be further assessed for eligibility. We conducted a full text screening as stated in “MATERIALS AND METHODS”. After this we included 20 studies in our review. We reported these steps in the following flow chart (Fig. 1).

PATIENT SELECTION

We researched literature and outlined noteworthy recommendations for patient selection for RPD (Table 1).

First, the evidence-based Miami guidelines set out some recommendations for patient selection (3). They do however state that there is limited comparative data available and further investigation is needed. These guidelines recommend that vascular resection should only be performed in high volume centers by highly experienced surgeons. Furthermore, they state that patients shouldn’t be excluded from RPD based on obesity, patient age, and previous abdominal surgery (3). Zureikat et al. (4) describes the first 500 RPDs of a single center and showed a
continued improvement of outcomes after 200 cases. It also details that the expansion of patient selection criteria did not impact outcomes such as operative time, conversion to open, blood loss, and clinically relevant postoperative pancreatic fistula (POPF).

There was an expansion of patients with higher Charlson comorbidity scores, patients with pancreatic ductal adenocarcinoma, patients who received neoadjuvant therapy, and vascular resections (4). Beane et al. researched the outcomes and learning curve of RPD with vascular resection. They showed a decrease in operation time after eight procedures and a learning curve around 35 cases. The group that performed this study first performed 80 RPDs before performing vascular resection. The results show comparable postoperative outcomes compared to RPD without vascular resection but did show an increase in mean estimated blood loss, conversion rate, and mean operation time (5). Kim et al. (6) demonstrated that an anatomical variation of the right hepatic artery (RHA) isn’t a contraindication for RPD with no significant differences in the pre- and postoperative outcomes compared to the normal RHA group. Obesity also isn’t a contraindication for RPD according to Girgis et al. (7) since they found a decrease in operative time, estimated blood loss, and POPF rate when compared to OPD with obesity. An increased number of POPF was seen after RPD compared to OPD in patients that were classified as intermediate risk for POPF before the procedure (8).

VOLUME CRITERIA

The following studies reported on volume criteria (Table 2).

The previously mentioned Miami guidelines describes a decreased complication rate when the annual volume per center is less than 20 RPD procedures and an increased mortality rate when this annual volume is less than 10 RPD procedures. It recommends an annual volume of 20 RPDs per center per year (3).

A retrospective study of 200 consecutive RPDs in an expert center reported improvements in estimated blood loss and conversions after overall 20 procedures, less pancreatic fistula after overall 40 procedures, and reduced operative time after overall 80 procedures (9).

Adam et al. (10) found a higher annual hospital volume of RPD is associated with improved outcomes, especially with annual center volumes exceed 22. Torphy et al. (11) describe reduced 90-day mortality in high-volume centers compared to low-volume centers and a higher risk of conversion for low-volume centers. Takahashi et al. (12) reported an improved operation time after 15 cases and a decrease in major complication rate after 30 cases. A single-center study studied 60 patients and divided them in two groups, the first 40 and the last 20. The last 20 RPD patients had a significantly shorter mean operation time and decreased mean blood loss compared to the first 40 patients (13). In a single surgeon study, operation time decreased after 33 procedures and this was associated with a decrease in delayed gastric emptying rate. After 40 procedures readmission rate decreased (14). Finally, a single surgeon study describes a significant decrease in operation time, hospital stay, and estimated blood loss after first 40 patients (15).

TRAINING PROGRAM

In the literature, we identified three training programs for minimally invasive pancreas surgery. One national training program for minimally invasive distal pan-

<table>
<thead>
<tr>
<th>Last author</th>
<th>Year</th>
<th>Country</th>
<th>Single/multicenter</th>
<th>Design</th>
<th>Cohort</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zureikat</td>
<td>2019</td>
<td>United States</td>
<td>Single</td>
<td>Retrospective review of prospectively maintained database 2008–2017</td>
<td>500 RPD</td>
<td>Patients with pancreatic ductal adenocarcinoma, who received neoadjuvant therapy and vascular resection are no contraindication for RPD</td>
</tr>
<tr>
<td>Beane</td>
<td>2019</td>
<td>United States</td>
<td>Single</td>
<td>Retrospective review of prospectively maintained database 2011–2017</td>
<td>380 RPD</td>
<td>Vascular resection isn’t a contraindication when performed by highly experienced RPD surgeons in high-volume centers</td>
</tr>
<tr>
<td>Kim</td>
<td>2016</td>
<td>United States</td>
<td>Single</td>
<td>Retrospective review of prospectively maintained database 2007–2015</td>
<td>73 RPD</td>
<td>Aberrant RHA isn’t a contraindication for RPD</td>
</tr>
<tr>
<td>Girgis</td>
<td>2017</td>
<td>United States</td>
<td>Single</td>
<td>Retrospective review of prospectively maintained database 2011–2015</td>
<td>261 OPD and 213 RPDs</td>
<td>For patients with obesity, RPD shows better outcomes compared to OPD</td>
</tr>
<tr>
<td>Napoli</td>
<td>2018</td>
<td>Italy</td>
<td>Single</td>
<td>Retrospective case–controlled analysis of a prospectively maintained database 2007–2014</td>
<td>227 OPDs and 82 RPDs</td>
<td>Higher rates of POPF are reported after RPD compared to OPD in patients with intermediate risk for POPF before the procedure</td>
</tr>
</tbody>
</table>

RHA: right hepatic artery; OPD: open pancreatoduodenectomy; POPF: postoperative pancreatic fistula; RPD: robotic pancreatoduodenectomy.
createctomy (16) and one national training program in laparoscopic pancreatoduodenectomy (17).

This review focuses on RPD and there are two training programs for RPD described in the literature, Knab et al. (18) predicts that a proficiency-based training program can decrease the learning curve and therefore improve outcomes of RPD, outlined in (Fig. 2). Nota et al. (19) extrapolates the training program from Knab et al. to a nationwide training program in the Netherlands but outcomes have not been reported yet.

Zureikat et al. describes the effects of the training program of Knab et al. The integration of resident and fellow training in RPD did not negatively affect outcomes. Outcomes even continued to improve (18).

### SUMMARY

This review highlights current selection criteria, evidence on volume cut-offs and the learning curve in RPD and summarized evidence on training programs on RPD.

As described, there are no contraindications such as obesity, vascular resection, patients with pancreatic ductal adenocarcinoma, patients who received neoadjuvant therapy, patients with an anatomical variation of the RHA for RPD, as long as these procedures are performed by specifically trained and experienced RPD surgeons, working in high volume centers. A minimum annual center volume of 20 RPDs is recommended by several studies and seems reasonable in our view. Because approximately 40%–50% of patients will initially be eligible for RPD in centers as vascular resection will initially not be performed this means that the average annual PD volume should be around 50 procedures per year.

Improved outcomes and a shortened learning curve were reported after a training program for RPD. This calls for proficiency-based training program implemented in all international centers performing RPDs. Knab et al. and Zureikat et al. proved that a sufficient training program for RPD can significantly reduce learning curve and improve patient safety.

This review highlights the relevance of good patient selection, surgeon training, and sufficient annual volume. Based on this criteria we can built toward quality registries for RPD, such as recently started in Europe by the European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS; www.e-mips.com). Such quality registries, which already existed in separate countries (20) as Germany and the Netherlands can report on the outcomes of RPD and allows centers to reflect on their own outcomes in relation to those of others. These systems are highly supported by both the Miami guidelines and

<table>
<thead>
<tr>
<th>Last author</th>
<th>Year</th>
<th>Country</th>
<th>Single/multicenter</th>
<th>Single surgeon</th>
<th>Design</th>
<th>Cohort</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asbun</td>
<td>2018</td>
<td>USA</td>
<td>Multi</td>
<td>No</td>
<td>Guidelines</td>
<td>Six studies about MIPD concerning volume</td>
<td>Recommends minimum of 20 annual MIPDs</td>
</tr>
<tr>
<td>Boone</td>
<td>2015</td>
<td>USA</td>
<td>Single</td>
<td>No</td>
<td>Retrospective review of a prospectively maintained database 2008–2014</td>
<td>200 RPD</td>
<td>Statistical improvements in EBL and conversion after 20 cases, decrease in POPF rate after 40 cases, decrease in OT after 80 cases</td>
</tr>
<tr>
<td>Adam</td>
<td>2017</td>
<td>USA</td>
<td>Multi</td>
<td>No</td>
<td>Retrospective review of a prospectively maintained database 2000–2012</td>
<td>865 MIPD</td>
<td>Decrease in postoperative complications in hospitals with a volume threshold of 22 annual cases</td>
</tr>
<tr>
<td>Torphy</td>
<td>2019</td>
<td>USA</td>
<td>Multi</td>
<td>No</td>
<td>Retrospective review of a prospectively maintained database 2000–2012</td>
<td>18,259 OPD and 3754 MIPD</td>
<td>Reduced 90-day mortality in high-volume centers compared to low-volume centers</td>
</tr>
<tr>
<td>Takahashi</td>
<td>2018</td>
<td>USA</td>
<td>Single</td>
<td>Yes</td>
<td>Retrospective review of a prospectively maintained database 2012–2016</td>
<td>65 RPD</td>
<td>Improved operation time after 15 cases and a decrease in major complication rate after 30 cases</td>
</tr>
<tr>
<td>Chen</td>
<td>2015</td>
<td>China</td>
<td>Single</td>
<td>No</td>
<td>Prospective, matched, mid-term follow-up study</td>
<td>60 RPD and 120 OPD</td>
<td>The last 20 RPD patients had a significantly shorter mean operation time and decreased mean blood loss compared to the first 40 RPD patients</td>
</tr>
<tr>
<td>Napoli</td>
<td>2016</td>
<td>Italy</td>
<td>Single</td>
<td>Yes</td>
<td>Retrospective review of a prospectively maintained database 2008–2014</td>
<td>70 RPD</td>
<td>Operation time decreased after the first 33 cases</td>
</tr>
<tr>
<td>Zhang</td>
<td>2019</td>
<td>China</td>
<td>Single</td>
<td>Yes</td>
<td>Retrospective review of a prospectively maintained database 2012–2016</td>
<td>100 RPD</td>
<td>Decrease in operation time, hospital stay, and estimated blood loss after first 40 patients</td>
</tr>
</tbody>
</table>

MIPD: minimally invasive pancreatoduodenectomy; EBL: estimated blood loss; POPF: postoperative pancreatic fistula; OPD: open pancreatoduodenectomy; OT: operating time; RPD: robotic pancreatoduodenectomy.
international organizations for hepato-pancreato-biliary (HPB) surgery.

DECLARATION OF CONFLICTING INTERESTS
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

FUNDING
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: MJW Zwart received funding from the board of directors from the Amsterdam UMC (location AMC) for studies on safe implementation of robot-assisted and laparoscopic pancreatic surgery. He also received funding from the Dutch Digestive Foundation, for studies on the before mentioned topics.

ORCID ID
L. R. Jones https://orcid.org/0000-0001-6286-5155

REFERENCES

Fig. 2. Training program according to Knab et al.